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ABSTRACT
High throughput EST and full-length cDNA sequenc-
ing have revealed extensive variations at the 30 ends
of mammalian transcripts. Whether all of these
changes are biologically meaningful has been the
subject of controversy, as such, results may reflect
in part transcription or polyadenylation leakage. We
selected here a set of tandem poly(A) sites predicted
from EST/cDNA sequence analysis that (i) are
conserved between human and mouse, (ii) produce
alternative30 isoformswithunusualsizefeaturesand
(iii) are not documented in current genome data-
bases, and we submitted these sites to experimental
validation in mouse tissues. Out of 86 tested poly(A)
sites from 44 genes, 84 were individually confirmed
using a specially devised RT-PCR strategy. We then
focused on validating the exon structure between
distant tandem poly(A) sites separated by over 3kb,
and between stop codons and alternative poly(A)
sites located at 4.5kb or more, using a long-distance
RT-PCR strategy. In most cases, long transcripts
spanning the whole poly(A)–poly(A) or stop-poly(A)
distance were detected, confirming that tandem
sites were part of the same transcription unit.
Given the apparent conservation of these long
alternative 30 ends, different regulatory functions
can be foreseen, depending on the location where
transcription starts.
INTRODUCTION
During mRNA maturation, mRNA precursors are
processed at their 30 ends in a two-step reaction (1).
The primary transcript is endonucleolytically cleaved
downstream of a stop codon, at a polyadenylation—
poly(A)—site, and adenylate residues are added to the 30
end to form a poly(A) tail. The 30 untranslated region
(30 UTR), that extends from the stop codon to the poly(A)
site provides binding sites for regulatory binding proteins
and plays a key role in mRNA localization, mRNA
stability and translation eﬃciency (2).
It is now established that most transcription units in
mammalian genes have multiple poly(A) sites (3,4). Based
on available SAGE, EST and cDNA data, the average
number of poly(A) sites per gene is 2.1–2.2 for human
genes and 1.5–3.3 for mouse genes (4–6). Two main types
of alternative polyadenylation proﬁles have been
described based on poly(A) site location on a transcript.
Alternative poly(A) sites may be located in the same
30 exon/30 UTR and referred to as tandem poly(A) sites,
or they may be located in alternative 30 exons (7,8).
The presence of multiple mRNA isoforms that diﬀer only
at their 30 ends in a non-coding region is often related to
diﬀerent stabilities and translation rates. In these cases,
the use of tandem poly(A) sites can positively or
negatively impact the amount of protein produced per
unit of precursor mRNA. The 30 most poly(A) site usually
is the strongest site among all sites, which correlates with
the longest mRNA isoform being usually the predominant
one (4,9). It has been hypothesized that alternative
polyadenylation acts through shortening of mRNA to
regulate RNA localization, translation and stability (4).
The structures of 30 UTRs have been analyzed in
diﬀerent species using diﬀerent approaches. In the human
genome, the average length of the 30 UTR is 1027nt for a
maximum length of 8555nt (10). Although several very
long-range polyadenylation sites have been described in
humans (10,11), such sites are probably under-reported
since technical problems are encountered to amplify and
clone the full-length sequence of long mRNAs. In a recent
study of EST/cDNA-supported poly(A) sites in the
human genome, we observed a signiﬁcant incidence of
poly(A) sites up to 10–15kb past the stop codon and
proposed that as many as 5000 human genes may have
unreported 30 extensions (12). Although we introduced
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predicted from cDNA data, there has been some
reluctance to accept as biologically meaningful results
from high throughput screens, since they include cryptic
or antisense transcripts as well as signiﬁcant levels of
erroneous sequences (13,14). In order to identify possibly
functional instances of alternative polyadenylation, we
also studied phylogenetically conserved poly(A) sites,
deﬁned as poly(A) sites that are located at the same
position in an alignment of orthologous human and
mouse 30 UTRs and supported by cDNAs or ESTs in both
species. We identiﬁed  500 genes with tandem conserved
poly(A) sites (15).
In this work, we select a test set of conserved, tandem
poly(A) sites producing alternative 30 isoforms with
unusual length features and submit them to individual
RT-PCR validation in mouse. Most of the cDNA/EST-
based predictions turn out to correspond to speciﬁc and
reproducible transcripts, providing evidence for a high
incidence of alternative transcripts with very long 30 UTRs
in the mouse transcriptome, for which corresponding
poly(A) sites are also conserved in humans.
MATERIALS AND METHODS
mRNApreparation and controls
Embryonic ﬁbroblast NIH 3T3 cells and embryonic
ﬁbroblasts from Balb/c wild-type mouse (MEF) wt were
kindly provided by Joel Tardivel (INSERM U624,
Marseille) and cultivated in DMEM (Invitrogen) and
10% (v/v) Fetal Calf Serum (Invitrogen). RNAs were
prepared from 70% conﬂuent cells using TRIzol reagent
(Invitrogen). mRNAs from thymic epithelial 427.1, thymic
stromal 1308.1, thymic medullary epithelial MTE, lym-
phoma WEHI, mastocytoma P815 and ﬁbroblast LMTK
cells were kindly provided by Dr Denis Puthier (INSERM
ERM206, Marseille). mRNAs were also obtained from
murine tissue (Balb/c mouse) using the TRIzol reagent.
Prior to RT-PCR, mRNAs were treated with a RNAse
free DNAse (Promega), according to the manufacturer’s
recommendations. Quality was assessed by analytical gel
and PCR ampliﬁcation with primers for beta actin
50-GACTCCGGTGACGGGGTCACC-30 and 50-CACG
ATGGAGGGGCCGGACTC-30. We conﬁrmed the
absence of ampliﬁcation from primers located down-
stream of poly(A) sites for six candidates having no other
described poly(A) site downstream of the tested one.
Primers used were 50-AATCCTTGGGCAACTTGATG-
30 and 50-TGGCCAGTTTTCCTTTTGAG-30 for Gmfb
(439bp), 50-CCCCATCCTCAGCAGATAAA-30 and 50-A
TGGATGGATGGGTACATGG-30 for Cdyl2 (375bp),
50-TTGTTGCTGTTTGAGGCTTG-30 and 50-AGGTGT
TGCAGACACAGCAG-30 for Hdh (494bp), 50-TTTGC
ACCCTTCACACTGTC-30 and 50-GCAGTTTTTAGCT
GCCCAAC-30 for Cpeb2 (360bp), 50-GCCTTGGAATG
GTTCACTGT-30 and 50-CCCCTTTTCCCTCATCAAA
T-30 for Klf7 (366bp), 50-TGTTGTGTGCCTCTCTCAG
G-30 and 50-ACCTGTGTGTGCACCTGTGT-30 for
Atp9a (434bp). Results are shown in Figure 1C for two
candidates, Cpeb2 and Atp9a.
RT-PCR
cDNAs were prepared from 1mg total RNAs with an
equimolar pool of three modiﬁed poly(T) primers: 50-TT
CTAGAATTCAGCATTCGCTTCTTTTTTTTTTTTTT
TTTA-30,5 0-TTCTAGAATTCAGCATTCGCTTCTTTT
TTTTTTTTTTTTTG-30,5 0-TTCTAGAATTCAGCATT
CGCTTCTTTTTTTTTTTTTTTTTC-30 using the super-
script II reverse transcriptase (Invitrogen). The reverse
transcription lasted 50min for individual poly(A) site
validation and 2h for other validations. For individual
poly(A) site validation, PCR was performed with the
Phusion high ﬁdelity PCR mix (Finnzymes) with an
annealing temperature of 608C and a 30s extension
at 728C for all experiments. Most of the PCRs were
done with the reverse adaptor primer (AP): 50-TTCTAGA
ATTCAGCATTCGCTTC-30 or a gene-speciﬁc reverse
primer and a gene-speciﬁc forward primer (list in
Supplementary Table 3). To validate transcripts with
long distance between two poly(A) sites or long 30 UTR,
the Platinium Taq DNA polymerase (Invitrogen) was used
and an annealing temperature between 55 and 628C was
chosen depending on the Tm of the reverse primers.
Extension was performed at 688C, for 1min/kb. PCR
products were resolved on 1–2% agarose gel, depending
on the expected size.
PCR product purification and digestion
PCR products were puriﬁed with the Qiaquick PCR
puriﬁcation kit (Qiagen) and submitted to digestions with
restriction enzymes at 378C for 2h. Digestion products
were resolved on a 1% agarose gel.
Real-time quantitative RT-PCR
Real-time RT-PCR ampliﬁcation was performed using
primer sets for GAPDH (50-GGGTGTGAACCAGGAG
AAAT-30 and 50-TTCCACAATGCCAAAGTTGT-30,
118bp), and Atp9A genes (50-CTACATTGCCTCCCTG
GTGT-30 and 50-ACAGCTGACCAAGGTGATGA-30
[103bp] to amplify both isoforms, 50-CATGCAAACAG
ACCCATCTC-30 and 50-GGATGCAAGTGCTGAAAA
GA-30 [105bp] for the largest isoform). Synthesis of the
ﬁrst-strand cDNA was carried out as previously described
with 5mg RNAs. The RT product was then ampliﬁed
for 40 cycles using the Power SYBR Green PCR Master
Mix according to the manufacturer’s recommendations
(Applied Biosystems), on ABI 7000 sequence detector
(2min at 508C, 10min at 958C, 15s at 958C, 30s at 608C,
30s at 728C). Serial dilutions of cDNA (5 logs) generated
from the Wehi and p815 cell lines were used to generate a
standard curve for each tested isoform and GAPDH,
to conﬁrm that they were all ampliﬁed with a comparable
andhigheﬃciency.Then,relativeexpressionofbothAtp9a
isoforms was evaluated with the comparative CT method.
Relative expression values for each isoform were expressed
asaratioofisoform expressionleveltoGAPDH expression
levelinthesametissue.Eachassaywasrepeatedthreetimes
(triplicate), a negative control without template or with
RT-RNAs wasalwaysconductedwitheveryampliﬁcation.
The PCR products were resolved on 1% agarose gels.
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Figure 1. Individual poly(A) site validation. (A) Outline of experiment. mRNAs are reverse-transcribed using a pool of poly(T)-derived primers
containing a sequence of 17T, with an adaptor sequence in its 50 end, and a one-nucleotide anchor in its 30 end (A, G or C). (A) The PCR
ampliﬁcation is done with a forward gene-speciﬁc primer for each tested poly(A) site (SP1 or SP2) and the adaptor primer (AP) as a reverse primer
and the PCR product are resolved on agarose gel. (B) When no satisfying result is obtained, a reverse gene-speciﬁc primer is also designed (SRP1 or
SRP2) that overlaps part of the poly(A) tail and the sequence just upstream the poly(A) site. B: Controls. Quality of samples was assessed by PCR
ampliﬁcation with primers for beta actin. mRNAs were treated with a RNAse-free DNAse and cDNAs were prepared with reverse transcriptase
(D for cDNA) or without (R for RT-). NTC stands for ‘no template control.’ Expected size: 651bp. (C) Absence of ampliﬁcation using primers
downstream of poly(A) site. A PCR ampliﬁcation was performed using the primers designed to validate the last poly(A) site, (Cpeb2, PAS2 [649bp
expected] and Atp9a, PAS2 [516bp expected]) or primers downstream of this last poly(A) site, i.e. located in intergenic DNA (Cpeb2, genomic
[360bp expected] and Atp9a, genomic [434bp expected]). Templates were cDNAs prepared with reverse transcriptase (cDNA) or without (RT-), or
genomic DNA (GEN). NTC stands for ‘no template control.’ (D) Example. RT-PCR is performed as described from the three pools of cDNAs
(A, B or C) for the two NM_175294 tested isoforms corresponding to use of poly(A) sites 4 (399bp expected) and 6 (573bp expected). Templates
were cDNAs prepared with reverse transcriptase (cDNA) or without (RT-). NTC stands for ‘no template control’.
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Alternative poly(A)site database construction
Initial poly(A) site prediction was performed through
mapping of ESTs and full-length cDNAs onto the human
and mouse genomes as described in Ara et al. (2006) (15).
We collected as putative tandem sites all sets of two or
more predicted poly(A) sites occurring in the 10kb region
downstream of the 30-most stop codon of an annotated
gene. This comprised sites lying within annotated 30 UTRs
and also a signiﬁcant number of sites lying in apparent
intergenic regions. In order to enrich this collection in
biologically signiﬁcant tandem sites, we aligned the 10kb
30 regions of orthologous human and mouse genes and
retained only those sites that were exactly superimposed
in the pairwise alignment and had EST/cDNA support
in both human and mouse. This short list of 1096
phylogenetically conserved tandem poly(A) sites from
about 500 genes is available in Supplementary Table 1 of
Ara et al. (2006) (15). These data were further enriched
through incorporation of SAGE tags uniquely supporting
transcript isoforms and expression information extracted
from cDNA, EST and SAGE library data. Tissue-speciﬁc
expression of 30 isoforms was assessed based on EST and
SAGE library counts followed by statistical tests of the
overrepresentation of libraries. Results are available as
part of the AltPAS database (http://tagc.univ-mrs.fr/pub).
A special user interface was devised to facilitate examina-
tion of the  1000 poly(A) sites and assist the following
selection procedure.
Candidateselection for experimental validation
We focused on the most intriguing candidate poly(A) sites
which were the ones located at long distances from each
other or from the stop codon, and which were not yet
annotated in the Ensembl human and mouse genome
databases (16). We performed two distinct candidate
selections. First, tandem alternative poly(A) sites were
sorted according to the length separating two consecutive
sites, and sites separated by a distance of 3000nt or more
were chosen for experimental validation. This group was
composed of 34 candidates representing 75 poly(A) sites,
some candidates having more than two conserved tandem
poly(A) sites. Second, the 30 most poly(A) site was sorted
for each gene of our gene list, and poly(A) sites located
over 4500nt from the 30-most stop codon were selected.
This group was composed of 34 candidates as well.
Twenty-two candidates were common to the two groups
that totaled 86 distinct poly(A) sites and transcripts. This
ﬁnal list contained all conserved tandem poly(A) sites
from the computational pipeline (15) satisfying the
topological criteria, only excluding genes annotated as
unnamed or incomplete.
The gene list and topology of tandem poly(A) sites are
presented in Table 1. Precise cleavage site location and
numbers of EST/cDNA supporting poly(A) sites in the
mouse genes and their human counterparts are shown in
Supplementary Table 1. A more detailed description of the
mouse sites is given in Supplementary Table 2, including
location and sequence of the poly(A) signal, presence of
SAGE or full-length cDNA supporting the transcript,
evaluation of the cleavage site homogeneity and presence
of AU-Rich Elements (ARE) and Upstream Sequence
Elements (USE) in surrounding sequences. Among the 86
selected poly(A) sites, 53 were associated with a canonical
AAUAAA poly(A) signal (61.1%), in agreement with
overall poly(A) signal frequencies (17). Comparison of the
signal sequence at the 30-most and the 50-most poly(A)
signals of candidates having only two tandem poly(A)
sites did not show a signiﬁcant diﬀerence in the
representation of the AAUAAA signal.
Selection of the cleavage site is determined mainly by
the distance between the upstream polyadenylation signal
and the downstream elements composed of U/GU-rich
elements (18), but seems to be quite imprecise (3,4,19,20).
We deﬁne cleavage site homogeneity as the ratio between
the number of EST-cDNA ending exactly at a given
cleavage site and the total number of EST-cDNA
supporting the poly(A) site. In our selection, only 17
transcripts had a ratio over 0.7, which reﬂects a high rate
of cleavage site heterogeneity. Whether this was due to
biological reality or technical artifacts such as misalign-
ments of low quality EST sequences remains to be
established.
We sought known regulatory sequences in the 30 UTR
(ARE) and in the vicinity of the poly(A) signal (USE)
(Supplementary Table 2). AREs are found in the 30 UTR
of many mRNAs and represent a common determinant
for mRNA instability. In the case of tandem poly(A) sites,
the use of the proximal poly(A) signal could result in
exclusion of a part of the 30 UTR harboring AREs (21).
Three classes of AREs have been described, two
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Figure 1. Continued.
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Nucleic Acids Research, 2007, Vol. 35, No. 6 1951AUUUA-containing classes and one U-rich region-
containing class (18). We scanned the region preceding
the poly(A) site of each transcript to search for the
AUUUA motif. For 50-proximal sites, the scanned region
was composed of the sequence between the stop codon
and the poly(A) site. For distal sites, the scanned region
ranged from the previous conserved poly(A) site to the
distal site. ARE densities were not signiﬁcantly diﬀerent
between proximal and distal sites (data not shown).
USEs are U-rich elements upstream of the poly(A)
signal that can positively enhance polyadenylation eﬃ-
ciency in a spacing-dependent way (22). We scanned the
100-nt-sequence upstream of each poly(A) signal for the
consensus USE sequence AU(2–5)GURA (22) or putative-
derived USE sequences AU(2–5)G/CU/ARA/U/C (21,23).
Most transcripts (67.4%) had at least one USE sequence
but no signiﬁcant diﬀerence could be established between
USE frequencies near proximal and distal poly(A) signals
(data not shown).
Validation ofindividual poly(A) sites
We experimentally validated the 30 extremities of all
individual candidates using RT-PCR. First, total mRNAs
were extracted from diﬀerent cell lines, treated with a
RNAse-free DNAse to remove genomic DNA contamina-
tion, and reverse-transcribed using a pool of poly(T)-
derived primers containing a sequence of 17T, a
50 adaptor sequence and a one-nucleotide anchor at
the 30 end (mixed A, G or C). These primers target the
beginning of the poly(A) tail of transcripts, since the
anchor must hybridize with the nucleotide just upstream
of the ﬁrst A of the poly(A) tail to allow extension
(Figure 1A). The beneﬁts of this method are (1) to
circumvent the problem of cleavage site heterogeneity, and
(2) to append the same adaptor sequence to all reverse–
transcribed cDNAs (Figure 1A). Sample quality was
assessed by PCR ampliﬁcation with primers for beta
actin (Figure 1B).
To ensure that long 30 isoform products were not the
result of genomic contamination, we also designed probes
targeting genomic DNA downstream of distal poly(A)
sites. This was done for six genes where no further poly(A)
site was predicted downstream of the long-distance site
tested. As expected, DNA ampliﬁcation was obtained with
the genomic primers using genomic DNA, but in no case
could we amplify any product using the genomic primers
and cDNA. Detailed controls are shown in Figure 1C for
two genes, Cpeb2 and Atp9a.
In order to speed up validation, cDNAs were pooled in
three samples: cDNAs from thymic origin, named group
A (cDNAs from 427.1, 1308.1 and MTE cells), cDNAs
from embryonic and/or ﬁbroblast origin, named group B
(LMTK, NIH 3T3 and MEF cells) and cDNAs from
oncogenic origin, named group C (WEHI and p815 cells).
PCR ampliﬁcation was then performed using a forward
gene-speciﬁc primer for each isoform and the adaptor
sequence as a common reverse primer (Figure 1A) and
PCR products were resolved on agarose gels. When
successful, this strategy typically produced a single band
for each targeted 30 variant. Examples of such PCR
ampliﬁcations are shown in Figure 1D. In some cases,
the expected polyadenylated transcripts were ﬁshed out
together with other transcripts corresponding to distinct
neighboring poly(A) sites, or partial cDNA sequences
caused by internal priming at adenine stretches, thus
producing multiple bands on the gel. When such
unsatisfactory results were obtained (no band or multiple
bands), a speciﬁc reverse primer was designed that
overlapped part of the poly(A) tail and the sequence just
upstream the poly(A) site (Figure 1A) and was used to
perform the PCR ampliﬁcation together with the forward-
speciﬁc primer.
Complete results are presented in Table 1 (column
‘individual PAS’) and with further detail in
Supplementary Table 3. When a single band was obtained
at the expected size, the poly(A) site was considered as
validated for the tested cDNA pool (note ‘Y’ in
Supplementary Table 3). When two bands were observed,
one at the expected size and one that could be explained
(because of its size) by the presence of a neighboring
poly(A) site or internal priming site, the site was also
considered as validated. When two or three bands were
observed, one at the expected size and at least one that
could not be explained, the poly(A) site was considered as
validated with reservation (noted ‘y’ in Supplementary
Table 3). Finally, when no band or no speciﬁc band
was obtained, the experiment was repeated to conﬁrm
that the negative ampliﬁcation was not due to a technical
problem and the site was not validated in this
cDNA pool (noted ‘N’ in Supplementary Table 3). Of
the 86 transcripts, only two were not validated in any of
the three pools of tested cDNAs: the two transcript
isoforms of the VCIP_MOUSE gene (poly(A) sites 2 and
8). As these poly(A) sites were supported by less than 3
ESTs, it is possible that these transcripts were either
spurious or expressed at a very low level and not
detectable with our method in our pools of cell lines.
Seventy-ﬁve transcript ends (87.2%) were validated in all
three cDNA pools.
Poly(A) sites with predicted tissue expression biases
were further tested using total mRNAs from 23 diﬀerent
murine tissues. Results are shown in Supplementary
Table 3. For all 31 transcripts with a predicted tissue
bias, RT-PCR conﬁrmed expression in the corresponding
tissues. Although many transcripts showed expression in
brain, this bias is not signiﬁcant when considering that
brain tissues have higher EST coverage and most of the
predicted expression biases were in brain.
Validation of tandem poly(A)sites
The previous experiment did not distinguish tandem
poly(A) sites, i.e. sites located in the same 30 exon, from
poly(A) sites resulting from alternative 30 exons. To
validate the tandem topology, one must check that no
intron lies between the two conﬁrmed poly(A) sites. This
validation was performed on 19 randomly selected
candidates from the ﬁrst validation group, using cDNAs
from NIH 3T3 and MEF cells. Reverse transcription was
performed with the same modiﬁed poly(T) primers
described previously. Then, PCR ampliﬁcation was
1952 Nucleic Acids Research, 2007, Vol. 35, No. 6performed using the speciﬁc forward primer used to check
the validity of the proximal poly(A) site and a speciﬁc
reverse primer for the distal poly(A) site that overlapped
part of the poly(A) tail (Figure 2A). This strategy should
reveal intervening introns as these would lead to shorter
PCR products than expected. Further, bands obtained in
agarose gels were puriﬁed and digested with restriction
enzymes, and digestion proﬁles were compared to those
expected from transcript sequences. Two positive diges-
tion proﬁles from two diﬀerent enzymes were required to
conﬁrm each transcript. Results obtained for the distal
tandem poly(A) sites of Gng12, a two-exon gene, are
shown in Figure 2B. The distance between the two poly(A)
sites is 3020nt. The forward primer targeted the ﬁrst exon
while the reverse primer targeted the transcript termina-
tion along with part of the poly(A) tail. The PCR product
was digested with BamHI or BglII. Selected primers and
results are listed in Supplementary Table 4, and results
are summarized in Table 1 (column ‘tandem’). Eighteen
out of 19 tandems were fully conﬁrmed as intron-less while
one (Ppm1a) could not be conﬁrmed by restriction
enzyme digestion, although band position was compat-
ible with a continuous transcript spanning the two
consecutive poly(A) sites. Only two of the 19 conﬁrmed
tandems (Gng12 and cpeb2) had previous support from
a FANTOM3 full-length cDNAs spanning the two
consecutive poly(A) sites.
Validation ofvery long30 UTR extensions
The 30 UTR of a mature mRNA extends from the stop
codon to the poly(A) site. For validation of exceptionally
long 30 UTRs (44.5kb), the forward primer was selected
so as to target a sequence upstream of the stop codon, in
most cases in the exon preceding the last exon (Figure 3A).
This validation was performed on 19 randomly selected
distal isoforms from the second group, using cDNAs from
NIH 3T3 and MEF cells. Two expected digestion proﬁles
were required to validate each transcript. As an example,
validation of the most distal human/mouse-conserved
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Figure 2. Tandem poly(A) site validation. (A) Outline of experiment. RNAs are reverse-transcribed into cDNAs using a pool of poly(T)-derived
primers as described in Methods. The PCR ampliﬁcation is done with the forward gene-speciﬁc primer used to validate the proximal poly(A) (SP1)
and a reverse gene-speciﬁc primer that targets the distal poly(A) site and overlaps part of the distal poly(A) tail (SRP2). Restrictions with restriction
enzymes are performed to assess the size. (B) Example. RT-PCR is performed as described from NIH3T3 and MEF mRNAs to test the poly(A) site
7 of Gng12 from cDNAs prepared with reverse transcriptase or without (RT-) or without template (NTC). The forward primer, that was used to
validate the poly(A) site 3 of the gene, targets the ﬁrst exon while the reverse primer targeted end of the transcript with part of the poly(A) tail
(scheme). The PCR product is digested with BamHI (expected products: 1438bp, 2447bp) or BglII (expected products: 2250bp, 798bp, 837bp) or
left undigested ( ).
Nucleic Acids Research, 2007, Vol. 35, No. 6 1953poly(A) site of Map3k2 is shown in Figure 3B. The
distance between the stop codon and poly(A) site was
8393nt. The forward primer targeted exon 18 while the
reverse primer targeted a sequence upstream the poly(A)
site and part of the poly(A) tail in exon 19 (Figure 3B).
The PCR product was digested with StuI or SpeI. Results
of this validation for 19 distal isoforms are shown together
with primers in Supplementary Table 5 and summarized in
Table 1 (column ‘long 30 UTR’). Twelve distal poly(A)
sites were fully validated by RT-PCR and restriction
digestion (noted ‘Y’), while six more yield PCR products
of expected sizes but could not be resolved by restriction
digestion (noted ‘NV’). Only one out of 19 long UTRs
tested (Syt7) was not conﬁrmed at all.
DISCUSSION
In mammalian cells, the cleavage/polyadenylation speciﬁc-
ity factor (CPSF) recognizes and binds the poly(A) signal
while the cleavage stimulation factor (CstF) binds the
U/GU-rich downstream element. Cooperative interactions
and assembly of CPSF and CstF with other proteins like
poly(A) polymerase (PAP) are important for cleavage of
the pre-mRNA and addition of  250 adenylate residues at
the 30 end (1). Choice of a poly(A) signal in a competitive
environment as it is the case for tandem poly(A) sites
seems to be a multifactorial process that involves steric
constraints (23), presence of enhancer sequences like USE
(21) and availability of cleavage/polyadenylation factors
and their modulators (7).
The majority of documented long-range, alternative
polyadenylation sites result from the analysis of high
throughput data such as EST sequences (4,11,12,15). A
recent EST and cDNA mapping on the human and mouse
genome has predicted on the order of 5000 poly(A) sites
lying in the 5–10kb region following annotated transcrip-
tion ends (12). However, as experimental conﬁrmations of
such long-range poly(A) sites are limited and their
biological signiﬁcance is still uncertain, gene-by-gene
ATT
A
ATT
A
Final PCR
product
PCR
(primers : SP/SRP2)
Agarose gel
Agarose gel
Enzyme
restriction
Digested
products 
Tandem
isoform
transcripts
ATT
A
mRNA 2
GAC
G
mRNA 1
ATT
A
RT
GAC
G Reverse transcript 1
Reverse transcript 2
Stop
Stop
>4500 nt A
B
Stop
Stop
Stop
Stop
Stop
SP
SRP2
GAC
G
Stop SP
Poly(A)/poly(T) sequences
Adaptor sequence
2000 bp
1000 bp
3000 bp
4000 bp
Map3k2
PAS3 Stop
8687 bp
Map3k2, PAS 3
8393 bp 1393 bp
DNA
ladder − NTC    RT- − StuI SpeI
Actin
8000 bp
10000 bp
500  bp 
Figure 3. Validation of transcripts with very long 30 UTR. (A) Outline of experiment. RNAs are reverse-transcribed into cDNAs using a pool of
poly(T)-derived primers. The PCR ampliﬁcation is done with a forward gene-speciﬁc primer that targets a sequence upstream the stop codon (SP)
and a reverse gene-speciﬁc primer that targets the distal poly(A) site and overlaps part of the distal poly(A) tail (SRP2). Digestions with restriction
enzymes are performed to assess fragment sizes. (B) Example. RT-PCR is performed as described from NIH3T3 and MEF mRNAs to test the
poly(A) site 3 of Map3k2 from cDNAs prepared with reverse transcriptase or without (RT-) or without template (NTC). The forward primer targets
the exon 18 while the reverse primer targeted end of the transcript on exon 19 with part of the poly(A) tail (scheme). The PCR product is digested
with StuI (expected products : 2393 bp, 2280 bp, 3859 bp, 155 bp) or SpeI (2664 bp, 3698 bp, 347 bp, 1978 bp) or left undigested (–).
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To perform individual RT-PCR validation we needed a
reasonably sized subset of long-range sites, hence further
selection criteria were required. We opted to focus only on
those  1000 tandem poly(A) sites that were conserved
between orthologous 30 regions in human and mouse.
Combining this with distance requirements (43kb
between sites, or 44.5kb from stop codon) we ended up
with a short list of 86 individual poly(A) sites from 44
diﬀerent genes. Our experimental validations showed that
(1) all but two tested poly(A) sites were real; (2) at least 18
out of 19 tested tandem sites were actually located in the
same exon and did not result from alternative splicing; and
(3) between 11 and 18 out of 19 tested long 30 UTR were
actually transcribed as a continuous block and were not
the product of independent transcription units.
The qualitative PCR strategy we used to validate
individual poly(A) sites does not preclude ampliﬁcation
of low abundance transcripts that may be of lesser
functional signiﬁcance. EST counts do not support a
lower expression of longer isoforms: the average numbers
of EST/isoform in our gene set are 21.5 and 21.4 for
shorter and longer isoforms, respectively. However,
certain long isoforms exhibit modest experimental sup-
port. For instance the distal site of Atp9a is supported by
3 ESTs versus 143 for the proximal site (Supplementary
Table 1), and is only conﬁrmed in the Wehi and p815 cell
lines (Supplementary Table 3). We further evaluated the
expression of both Atp9a isoforms with real-time quanti-
tative RT-PCR (Supplementary Figure 1). Expression of
the longest isoform was very low indeed in the Wehi and
p815 cell lines but drastically increased in kidney
(72X increase) and testis (53X increase). This indicates
that even though a transcript may be detected at low
abundance in cell lines, a higher expression in speciﬁc
tissues or under speciﬁc conditions is possible and should
not be overlooked, as context-speciﬁc expression confers a
real biological interest to transcript isoforms.
Among 22 validated 30 UTR extensions (either through
ampliﬁcation of entire UTRs or inter-poly(A) site regions),
12 had support from FANTOM3 full-length cDNAs.
Interestingly, in seven cases, the full-length cDNA from
which a distal poly(A) site was predicted was com-
pletely disjointed from the annotated transcription unit.
An example is shown in Figure 4 for gene Tmem33
coding for the DB83 membrane protein (24). Although
the FANTOM3 cDNA supporting the distal site is
located at about 2.5kb from the end of the transcription
unit, we showed by RT-PCR that another transcript
exists (bottom red strip) that bridges this gap while
encompassing the complete 5.2kb UTR. Considering
that we observed seven such instances of gap-spanning
out of 12 poly(A) sites with full-length cDNA support
(Sos1, NM_028906, Hoxd4, Tmem33, Gas7, F34A,
Map3k2), we may expect extended 30 UTRs of these
sort to occur quite frequently. It is not clear however,
how much of these transcripts span the entire coding
region. Only one of the 12 full-length cDNAs corre-
sponding to distal poly(A) sites starts at exon one of the
annotated gene. In all other cases, cDNAs have their
transcription start sites (TSS) in internal exons or in the
last exon. As multiple TSSs arise in the 30 regions of
transcription units (13,14), we expect that a fraction of
our long-range poly(A) sites correspond to such ‘late’
TSSs. However, examples of ‘gap spanning’ such as
Tmem33 show us that for a given TSS in the 30 UTR,
other TSSs that are closer to the gene 50 end may also
exist that are not present in current full-length cDNA
collections. The majority of the long 30 UTRs we tested
had a TSS in the coding region or upstream, as forward
PCR primers were always chosen upstream of the stop
codon, therefore they contained at least a part of the
coding region. Depending on the integrity of this coding
region, the functions of these extended transcripts may
involve protein expression control as in the COX-2
example above or more indirect mechanisms. For
2.35kb
Figure 4. Example of an extended UTR bridging the gap to a distant full-length cDNA. Screenshot from the Riken genomic element viewer (http://
fantom3.gsc.riken.jp/) displaying both full-length cDNAs and CAGE tags (transcription starts) for gene Tmem33. The stop codon position is
indicated with a yellow triangle. The bottom red strip represents the RT-PCR validated transcript (50 end is not determined). We located a putative
poly(A) site for gene Tmem33 at around 5.2kb from the stop codon, supported by a single full-length cDNA (highlighted). The 2.35kb gap between
this unique cDNA and the longest Tmem33 transcript caused Riken to predict two independent transcription units (TUs) for these entities.
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proteins away from the shorter isoforms, or be involved
in sense–antisense regulation of a ﬂanking gene (25).
Some 30 UTR segments can be more conserved than
coding exons (26), reﬂecting an unexpected selective
pressure in this region. As multiple targets for regulatory
proteins or RNAs are hosted in 30 UTRs (27), one can
hypothesize that conservation of speciﬁc alternative
30 ends together with speciﬁc 30 UTR elements might
reﬂect novel regulatory mechanisms. This is observed for
instance in the alternative polyadenylation of cycloox-
ygenase 2 (COX-2). The proximal and the distal poly(A)
sites of human COX-2 are located at 0.6 and 2.5kb from
the stop codon respectively, a pattern conserved in mouse
and rat. Two ARE-rich regions located on both sides of
the ﬁrst poly(A) site and bound by two proteins with
opposite eﬀects have been described. The RNA stability
factor HuR binds the proximal AREs, enhancing the
stability of both isoforms (28) while tristetraprolin binds
only the most distal AREs and destabilizes the longer
isoform (29). The two poly(A) sites are regulated in a
tissue-speciﬁc manner and the proximal site contains three
USEs that are crucial for its usage (21). This example
shows that usage of distal poly(A) sites can impact protein
synthesis in response to environmental constraints such as
cell cycle progress or growth factor stimulation. All the
tandem sites conﬁrmed here are conserved in humans and
therefore are candidates for such regulatory mechanisms
involving speciﬁc target sites in the longer isoform.
As these long transcripts are relatively diﬃcult to clone,
they may be under-represented in high throughput cDNA
collections. Additional eﬀorts are required to assess the
full extent of these transcripts and their relevance to the
overall transcriptional landscape.
SUPPLEMENTARY DATA
Supplementary Data is available at NAR Online.
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